Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover ...

A CNBC investigation into illegal weight loss drugs reveals a marketplace where criminals brazenly counterfeit the drugs or ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

Therapies that deliver hydrogen sulfide to cells could one day become the basis of new treatments for obesity and related ...

A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

New-generation anti-obesity drug Wegovy, made by the same company that created Ozempic, is now available in France – but it ...

France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...

Medicare is prohibited by law from covering GLP-1 drugs for weight loss. But many beneficiaries can access the drugs anyway.

The cost of taking weekly injections of popular anti-obesity medications liraglutide (Saxenda) or semaglutide (Wegovy) ...

Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...

As part of our series In Good Health, we discuss these new medications and the falling rate of obesity.